Management of cytomegalovirus infection by weekly surveillance after renal transplant: Analysis of cost, rejection and renal function

Nephrology Dialysis Transplantation

Volumn 18, Issue 9, 2003, Pages 1891-1898

  Geddes, Colin C ^a   Church, Colin C ^a   Collidge, Tara ^a   McCruden, Elizabeth A B ^a   Gillespie, Graeme ^a   Matthews, Elaine ^a   Hainmueller, Anke ^a   Briggs, J Douglas ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cost; Cytomegalovirus; Kidney transplant; Polymerase chain reaction; Prophylaxis; Renal function

Indexed keywords

ALLOPURINOL; ANTIVIRUS AGENT; AZATHIOPRINE; BASILIXIMAB; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; GANCICLOVIR; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POLYCLONAL ANTIBODY; PREDNISOLONE; TACROLIMUS; VALACICLOVIR;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; FEMALE; HIGH RISK PATIENT; HOSPITAL COST; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; KIDNEY DONOR; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALE; PERIODIC MEDICAL EXAMINATION; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECIPIENT; RISK ASSESSMENT; SERODIAGNOSIS; TREATMENT PLANNING;

ADULT; COSTS AND COST ANALYSIS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POPULATION SURVEILLANCE; TREATMENT OUTCOME;

EID: 0041883562     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg283     Document Type: Article

References (20)

1. The EBPG Expert Group on Renal Transplantation. The transplant recipient from initial hospitalization to 1 year post-transplant. Nephrol Dial Transplant 2000; 15: 52-85
2. Jassal SV, Roscoe JM, Zaltzman JS et al. Clinical practice guidelines: prevention of cytomegalovirus disease after renal transplantation. J Am Soc Nephrol 1998; 9: 1697-1708
3. Lowance D, Neumayer HH, Legendre CM et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340: 1462-1470
4. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356: 645-649
5. Emery VC. Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 2001; 11: 83-86
6. Brennan DC, Storch GA, Lippman BJ. Preemptive ganciclovir therapy in renal transplantation. Ann Intern Med 1996; 124: 693
7. Hart GD, Paya CV. Prophylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 2001; 11: 73-81
8. Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. J Am Med Assoc 1989; 261: 3607-3609
9. Matas AJ, Gillingham KJ, Payne WD, Najarian JS. The impact of an acute rejection episode on long-term renal allograft survival. Transplantation 1994; 57: 857-859
10. Salmela KT, Vanrentergem Y, van Hoof J, Squifflet JP, the European Tacrolimus/MMF Renal Transplantation Study Group. Efficacy and safety of three months of tacrolimus/steroids/MMF followed by a controlled withdrawal of steroids or MMF: results of a large prospective multicentre trial [abstract]. Am J Transplant 2001; 1: 246A
11. Taylor-Wiedeman J, Sissons JG, Borysiewicz LK, Sinclair JH. Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J Gen Virol 1991; 72: 2059-2064
12. Nicoll S, Brass A, Cubie HA. Detection of herpes viruses in clinical samples using real-time PCR. J Virol Methods 2001; 96: 25-31
13. Storch GA, Buller RS, Bailey TC et al. Comparison of PCR and pp65 antigenemia assay with quantitative shell vial culture for detection of cytomegalovirus in blood leukocytes from solid-organ transplant recipients. J Clin Microbiol 1994; 32: 997-1003
14. Steddon SJ, Ball EA, Aitken C, Rudge CJ, Raftery MJ, Yaqoob MM. CMV prophylaxis: infection or disease as target? [abstract]. J Am Soc Nephrol 1999; 10: 766A
15. Legendre CM, Norman DJ, Keating MR, Maclaine GD, Grant DM. Valaciclovir prophylaxis of cytomegalovirus infection and disease in renal transplantation: an economic evaluation. Transplantation 2000; 70: 1463-1468
16. Brennan DC, Garlock KA, Singer GG et al. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation 1997; 64: 1843-1846
17. Rayes N, Seehofer D, Schmidt CA et al. Prospective randomized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation. Transplantation 2001; 72: 881-885
18. Koetz AC, Delbruck R, Furtwangler A et al. Cytomegalovirus pp65 antigen-guided preemptive therapy with ganciclovir in solid organ transplant recipients: a prospective, double-blind, placebo-controlled study. Transplantation 2001; 72: 1325-1327
19. Roberts TC, Brennan DC, Buller RS et al. Quantitative polymerase chain reaction to predict occurrence of symptomatic cytomegalovirus infection and assess response to ganciclovir therapy in renal transplant recipients. J Infect Dis 1998; 178: 626-635
20. Emery VC, Hassan-Walker AF. Focus on new drugs in development against human cytomegalovirus. Drugs 2002; 62: 1853-1858